Gamida Cell Ltd (NASDAQ:GMDA) was the target of a large decline in short interest in September. As of September 15th, there was short interest totalling 28,300 shares, a decline of 10.2% from the August 15th total of 31,500 shares. Based on an average daily volume of 39,000 shares, the short-interest ratio is currently 0.7 days. Currently, 0.3% of the company’s stock are short sold.
A number of equities research analysts have weighed in on the company. Zacks Investment Research raised Gamida Cell from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a research report on Monday, August 12th. JMP Securities began coverage on Gamida Cell in a research report on Friday, September 20th. They set an “outperform” rating and a $16.00 target price for the company. ValuEngine raised Gamida Cell from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Oppenheimer set a $18.00 price target on Gamida Cell and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Eight research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $16.43.
Shares of GMDA traded down $0.08 during trading hours on Monday, hitting $4.07. The company had a trading volume of 5,422 shares, compared to its average volume of 30,787. The company has a market capitalization of $111.18 million and a PE ratio of -0.39. The company has a current ratio of 4.47, a quick ratio of 4.47 and a debt-to-equity ratio of 0.23. Gamida Cell has a one year low of $2.93 and a one year high of $15.41. The company’s fifty day moving average price is $3.87 and its two-hundred day moving average price is $6.59.
Gamida Cell (NASDAQ:GMDA) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.87) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.32). Analysts forecast that Gamida Cell will post -1.16 earnings per share for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rock Springs Capital Management LP bought a new position in shares of Gamida Cell in the 2nd quarter worth $5,080,000. Noked Capital LTD purchased a new position in Gamida Cell during the 2nd quarter worth $1,035,000. Bank Hapoalim BM purchased a new position in Gamida Cell during the 2nd quarter worth $195,000. EcoR1 Capital LLC purchased a new position in Gamida Cell during the 2nd quarter worth $265,000. Finally, Royal Bank of Canada purchased a new position in Gamida Cell during the 2nd quarter worth $71,000. 25.86% of the stock is owned by hedge funds and other institutional investors.
About Gamida Cell
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Recommended Story: What are Bollinger Bands?
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.